Lenalidomide-Promomed (multiple myeloma drug)

The main articles are:

• Cancer (cancer)
• Cancer treatment
• Drugs to treat cancer

2022: Drug registration

Promomed HA registered Lenalidomide for the treatment of multiple myeloma. The anticancer drug was the fourth in the company's oncoportfel. This became known in June 2022.

Multiple myeloma is one of the most common diseases in oncology-matology, the second most common tumor of the hematopoietic system. Until recently, it was considered a disease of the elderly, but over the past few years, the disease has been increasingly detected in people aged 45-50 years. Over 4000 thousand cases are recorded annually in Russia alone.

The drug contains the active substance lenalidomide, which affects the immune system of the body and has a direct effect on tumor cells by inhibiting their growth.

The formation of a portfolio of medicines aimed at therapy of socially significant, including cancer, is one of the most important tasks for Promomed Group of Companies as part of a strategy to solve global medical problems, save lives and significantly improve patient health. When launching new drugs on the market, including generic ones, the company offers patients effective and safe drugs due to the high quality of their substances, the manufacturability of production processes, the highest quality control standards.

Lenolidomide-Promomed will be available in 2.5 mg to 25 mg capsules, which is consistent with the standard regimens.

Like most drugs manufactured by Promomed Group of Companies, this drug is included in the VED list.